Stockreport

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Seres Therapeutics, Inc.  (MCRB) 
Last seres therapeutics, inc. earnings: 11/5 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.serestherapeutics.com
PDF New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial barri [Read more]